Sana Biotechnology (SANA) Corporate presentation summary

Addressing unmet needs in type 1 diabetes

• Over 10 million people globally live with type 1 diabetes, facing significant disease burden and reduced life expectancy despite current therapies.

• Insulin replacement is not curative, and patients seek alternatives that address both daily management and long-term complications.

Hypoimmune technology and clinical validation

• Hypoimmune gene edits enable allogeneic islet cell transplantation without immunosuppression, overcoming a major barrier in cell therapy.

• Clinical trial with UP421 showed safety, immune evasion, and cell survival for at least one year in a T1D patient without immunosuppression.

• No immune response detected toward HIP islet cells at 12 months, confirming durable immune evasion.

SC451 program and development milestones

• SC451 is a stem cell-derived, hypoimmune islet cell therapy aiming for a single, curative treatment for T1D without immunosuppression.

• Manufacturing scale-up, regulatory dialogues, and clinical planning advanced in 2025, with IND filing and Phase 1 trial targeted for 2026.

• Phase 1 trial will focus on safety, cell survival, immune evasion, and endogenous insulin production, with potential for insulin independence within 3-6 months.